On Monday, Cara Therapeutics Inc (NASDAQ: CARA) opened lower -6.08% from the last session, before settling in for the closing price of $0.38. Price fluctuations for CARA have ranged from $0.23 to $1.15 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 115.17%. With a float of $45.83 million, this company’s outstanding shares have now reached $54.85 million.
Considering the fact that the conglomerate employs 55 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 84.43%, operating margin of -944.9%, and the pretax margin is -1099.76%.
Cara Therapeutics Inc (CARA) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Cara Therapeutics Inc is 16.56%, while institutional ownership is 24.70%. The most recent insider transaction that took place on Nov 04 ’24, was worth 1,064. In this transaction PRESIDENT AND CEO of this company sold 3,668 shares at a rate of $0.29, taking the stock ownership to the 168,768 shares. Before that another transaction happened on Aug 01 ’24, when Company’s PRESIDENT AND CEO sold 4,149 for $0.35, making the entire transaction worth $1,452. This insider now owns 172,436 shares in total.
Cara Therapeutics Inc (CARA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Cara Therapeutics Inc (NASDAQ: CARA) Trading Performance Indicators
Check out the current performance indicators for Cara Therapeutics Inc (CARA). In the past quarter, the stock posted a quick ratio of 4.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.75, a number that is poised to hit -0.38 in the next quarter
Technical Analysis of Cara Therapeutics Inc (CARA)
Compared to the last year’s volume of 0.88 million, its volume of 1.89 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 57.39%. Additionally, its Average True Range was 0.06.
During the past 100 days, Cara Therapeutics Inc’s (CARA) raw stochastic average was set at 44.01%, which indicates a significant increase from 44.01% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 210.68% in the past 14 days, which was higher than the 99.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3078, while its 200-day Moving Average is $0.4506. Nevertheless, the first resistance level for the watch stands at $0.3867 in the near term. At $0.4183, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.4467. If the price goes on to break the first support level at $0.3267, it is likely to go to the next support level at $0.2983. Now, if the price goes above the second support level, the third support stands at $0.2667.
Cara Therapeutics Inc (NASDAQ: CARA) Key Stats
There are currently 54,856K shares outstanding in the company with a market cap of 19.47 million. Presently, the company’s annual sales total 20,970 K according to its annual income of -118,510 K. Last quarter, the company’s sales amounted to 2,560 K and its income totaled -12,480 K.
